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Background: In trials of long-acting bronchodilators, health status is an important trial outcome, however the 
influence of baseline severity on response measured by St George’s Respiratory Questionnaire (SGRQ) is not 
known. We have compared SGRQ changes between patients with chronic obstructive pulmonary disease (COPD) 
of mild-moderate severity or dyspnea (Global initiative for chronic Obstructive Lung disease [GOLD] grades 1 
and 2; modified Medical Research Council [mMRC] grades 1 and 2) to those with severe-very severe severity or 
dyspnea (GOLD grades 3 and 4; mMRC grades 3 and 4). 
Methods: Combined individual patient data from the COPD Biomarkers Qualification Consortium database (trials 
of long-acting bronchodilators) were used comprising of patients from short-term (≤1-year duration; n=10802) 
and medium-term (2-4 years’ duration; n=8963) studies. A repeated measures analysis of variance (ANOVA) was 
used to determine the effects of baseline severity (GOLD/mMRC) on SGRQ response to treatment. All treatment 
arms were combined.
Results: In short-term studies, milder patients showed a greater response than those with more severe disease in 
terms of GOLD grade (partial Eta2=0.03, p<0.0001) and mMRC grade (partial Eta2=0.05, p<0.0001). Similar results 
were seen in the medium-term studies (partial Eta2=0.02, p<0.0001; mMRC: partial Eta2=0.05, p<0.0001,).
Conclusions: Patients with less severe airflow limitation and less severe dyspnea showed larger improvements in 
SGRQ score than more severely obstructed or dyspneic patients. Although these severity influences are small (2%-
5% of the variance in SGRQ score), they do suggest that pre-specified separate analyses are warranted to test for 
differences in response, based on baseline severity.
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Introduction
Long-acting bronchodilators (LABs) form the mainstay 
of treatment for chronic obstructive pulmonary disease 
(COPD).1 They are appropriate for symptomatic 
patients of all degrees of severity, although there is 
little information about which patients benefit most in 
terms of health-related quality of life (HRQL). Unlike 
trials of treatments to reduce exacerbations, clinical 
trials for symptomatic treatments tend to recruit patents 
with a wide range of severity. To test whether there 
were differences in change in St George’s Respiratory 
Questionnaire (SGRQ) scores that were dependent 
on baseline severity, we used the COPD  Biomarkers 
Qualification Consortium (CBQC) database of clinical 
trials in COPD to compare response to SGRQ between 
patients with mild-moderate airflow limitation (Global 
initiative for chronic Obstructive Lung Disease [GOLD] 
grades 1 and 2) and those who were severe-very severe 
(GOLD grades 3 and 4).1  In addition, we compared 
Methods
Identification of Clinical Trials
The CBQC database of clinical trials in COPD was 
used for this analysis.2 This contains 18 randomized 
controlled trials (RCTs) and 3 observational studies 
which include SGRQ data. Only RCTs that included 
a treatment arm with placebo or long-acting 
bronchodilator (long-acting beta2-agonists and long-
acting anti-muscarinic agents) were used in this analysis 
(N=17). Details of the RCTs included in the analysis are 
described elsewhere,3 and further details are contained 
in the online data supplement to that publication. All 
patients who had a baseline SGRQ score were included 
in these analyses. All analyses used fully anonymized, 
pooled data, so ethics and institutional review board 
approval were not required. Appropriate approvals and 
written informed consent had been obtained originally 
for all the included studies.
The 17 RCTs were categorized by study duration: 
short-term (≤1-year duration) comprising 14 
trials with 10802 participants (placebo=3670; 
bronchodilator=7132), and medium-term (2-4 years’ 
duration) comprising 3 trials with 8963 participants 
(placebo=4184; bronchodilator=4779). The 2 types of 
trials were analyzed separately to test for consistency of 
findings across studies of different duration. Only 1 of 
the medium-term trials lasted for 4 years so the analysis 
was confined to the first 3 years of that trial. The 
patients were categorized into lower and higher airway 
function (GOLD grades 1 and 2 versus GOLD grades 
3 and 4) and those with less or more breathlessness 
(mMRC grades 1 and 2 versus mMRC grades 3 and 4). 
Grouping of severity categories to provide 2 subgroups 
rather than 4 individual groups, was required to ensure 
a more even distribution of patients in each subgroup, 
since there were relatively few patients in the least and 
most severe groups, whether GOLD grade, or mMRC 
grade.
Statistical Analysis
For each trial dataset (i.e., short-term or medium-term), 
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demographic characteristics are presented as mean and 
standard deviation (SD). Comparisons between groups 
were performed using t-tests for continuous variables 
and chi-square tests for categorical variables.
To assess how the degree of limitation in airway 
function (GOLD grades 1 and 2 versus GOLD grades 3 
and 4) and breathlessness (mMRC grades 1 and 2 versus 
mMRC grades 3 and 4) at baseline affects the SGRQ 
total score over the course of treatment with LABs, a 
repeated measures analysis of variance (ANOVA) was 
conducted. Separate models were run for GOLD (grades 
1 and 2 versus grades 3 and 4) and mMRC (grades 1 
and 2 versus grades 3 and 4). The dependent variable 
for these models was SGRQ total score and each model 
had 1 between participants factor (either GOLD or 
mMRC groups), and 1 within participants factor (time). 
For short-term trials, the study visits (time) included 
baseline and 1, 3, 6 and 12 months. For the medium-
term trials, the study visits included baseline and 6, 12, 
24, and 36 months. The main effect for time, GOLD or 
mMRC, and the interaction term were all evaluated; 
however, the primary hypothesis was centered on the 
interaction between GOLD/mMRC and time. Baseline 
covariates included baseline SGRQ score, age, sex, body 
mass index (BMI), World Health Organization socio-
economic status of the patient’s country (low, medium 
or high) and smoking status (former or current). In 
addition, baseline mMRC grade was included for models 
that tested the effect of GOLD grade on SGRQ response 
and baseline GOLD grade was included in models 
that tested the effect of mMRC grade.  The following 
hypotheses were evaluated for the ANOVA models: 
1. There will be a main effect for GOLD and mMRC, 
with more severe groups (GOLD grades 3 and 4 and 
mMRC grades 3 and 4) reporting higher SGRQ scores 
(HRQL) relative to the less severe groups (GOLD grades 
1 and 2 and mMRC grades 1 and 2). 
2. The response to treatment will be different (in either 
direction) between patients with more or less severe 
disease (as defined).
3. There will be a main effect for time, indicating that 
SGRQ scores change over the course of treatment with 
LABs in both the short-term (up to 12 months) and 
medium-term (up to 36 months). Given that COPD 
is a progressive condition, treatment with LABs often 
results in an initial improvement in symptoms, and 
subsequent deterioration,4,5 a non-linear effect of time 
was modeled. 
4. There will be no significant interaction between 
Results
Baseline Characteristics 
Short-term Trials - Demographics
By the nature of the categorization at baseline, mean 
forced expiratory volume in 1 second (FEV1) in GOLD 
grades 1 and 2 and mMRC grades 1 and 2 patients was 
higher (62.3% and 51.1% predicted) than in patients 
in GOLD grades 3 and 4 and mMRC grades 3 and 4 
(37.6% and 44.2% predicted respectively), Table 1. 
Similarly, SGRQ scores were worse (higher) in patients 
in GOLD grades 3 and 4, and those that reported greater 
breathlessness on the mMRC scale (GOLD grades 3 
and 4=49.9 versus GOLD grades 1 and 2=41.1; mMRC 
grades 3 and 4=61.1 versus mMRC grades 1 and 2=45.8; 
p<0.0001), Table 1. Patients in the more severe groups 
(GOLD grades 3 and 4 and mMRC grades 3 and 4) were 
more likely to have experienced an exacerbation in the 
12 months leading up to the baseline study visit relative 
to the less severe groups (GOLD grades 1 and 2 and 
mMRC grades 1 and 2) (p<0.0001).   
The FEV1 percent predicted was lower in GOLD 
grades 3 and 4 (37.6%) compared with mMRC grades 
3 and 4 (44.2 %). There were proportionally more men 
in GOLD grades 3 and 4 (73.8%) than in mMRC grades 
3 and 4 (62.4%). Otherwise, the 2 methods of assessing 
severity identified patients of a similar age and BMI 
and broadly similar proportions of patients in terms 
of: socio-economic status, smoking status, history of 
exacerbations and hospitalization (Table 1). 
GOLD or mMRC with time, indicating that the rate of 
change in SGRQ with LAB treatment does not vary 
based on the degree of limitation in airway function 
(GOLD grades 1 and 2 versus GOLD grades 3 and 
4) and breathlessness (mMRC grades 1 and 2 versus 
mMRC grades 3 and 4).  
The size of the databases may have resulted in some 
of the analyses being overpowered, resulting in small 
differences attaining statistical significance. In view 
of the number of study participants and the possible 
number of comparisons, significance was accepted at 
p<0.01. Attention should be paid to the size of the effect, 
rather than the p-value. For this reason, the partial-
Eta squared effect size is reported for all effects, and 
the following rules of thumb were utilized to facilitate 
interpretation: small (0.01), medium (0.06), and large 
(0.14).6,7
135 Predictors of Change in SGRQ Score
journal.copdfoundation.org   JCOPDF © 2017 Volume 4 • Number 2 • 2017
For personal use only. Permission required for all other uses.
Medium-term Trials - Demographics
The pattern of baseline findings in the medium-term 
trials was similar to those seen with the short-term 
trials, i.e., the differences in FEV1 and SGRQ between 
the GOLD and mMRC subgroups reflected patient 
categorization at baseline (Table 2). The more severe 
groups (GOLD grades 3 and 4 and mMRC grades 3 and 
4) were more likely to have experienced an exacerbation 
in the 12 months leading up to the baseline visit 
compared with the less severe groups. The 2 methods 
of severity assessment identified patients with similar 
characteristics, with the exception that SGRQ scores 
were worse in patients with mMRC grades 3 and 4 than 
in GOLD grades 3 and 4 (60.0 versus 50.3), Table 2. 
The FEV1 percent predicted was almost identical in 
patients in GOLD grades 3 and 4 and mMRC grades 3 
and 4 (36.9% versus 36.8 %), Table 2.  
SGRQ Response in GOLD Grades 1 and 2 
versus GOLD Grades 3 and 4 Groups 
In the short-term dataset, the repeated measures 
ANOVA indicated that the main effect for airflow 
limitation was significant (F1, 30677=1042.4, p<0.0001, 
partial Eta2=0.03), with patients with greater airflow 
limitation reporting worse scores for SGRQ. Post hoc 
tests at each time point show that the improvement in 
SGRQ score from baseline in the GOLD grades 3 and 4 
group was significantly less than in patients in GOLD 
grades 1 and 2 (Figure 1). The average difference was 
approximately 3 units. Both the linear (F1, 30677=401.2, 
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p<0.0001, partial Eta2=0.01) and quadratic effects for 
time (F1, 30677=296.0, p<0.0001, partial Eta2=0.01) were 
also significant, but both accounted for a very small 
proportion of the model variance. While the plots in 
Figure 1 suggest that the SGRQ differences appeared 
to widen over time, and the interaction between GOLD 
status and time was statistically significant, the effect 
size was negligible (F1, 30677=4.56, p=0.03, partial 
Eta2=0.0001). 
The pattern seen in the medium-term trials was 
similar: the GOLD main effect (F1, 27872=453.1, p<0.0001, 
partial Eta2=0.02), linear effect of time (F1, 27872=142.9, 
p<0.0001, partial Eta2=0.005), quadratic effect of time 
(F1, 27872=114.2, p<0.0001, partial Eta2=0.004), and 
GOLD x time (F1, 27872=1.50, p=0.22 partial Eta2=0.0001). 
Again, at 3 out of 4 time points, the response in GOLD 
grades 3 and 4 was significantly smaller than in GOLD 
grades 1 and 2 (Figure 2). Importantly, by 24 months, 
patients in GOLD grades 3 and 4 had returned to base 
line, whereas those in GOLD grades 1 and 2 remained 
significantly better than at baseline, even at 36 months 
(p=0.0018).
SGRQ Response Between mMRC Grades 1 and 
2 versus mMRC Grades 3 and 4 Groups 
In the short-term dataset, the repeated measures ANOVA 
indicated that the main effect for mMRC was significant 
(F1, 20606=1205.0, p<0.0001, partial Eta2=0.05). The post 
hoc analysis of change from baseline showed that at 1, 3 
and 6 months, patients with mMRC grades 1 and 2 had 
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a significantly larger improvement in SGRQ than those 
with mMRC grades 3 and 4 (Figure 3). At 12 months, the 
scores converged, but it will be noted that the standard 
errors for mMRC grades 3 and 4 widened considerably 
from those at 6 months.  Both the linear (F1, 20606=296. 
9, p<0.0001, partial Eta2=0.01) and quadratic effects for 
time (F1, 20606=247. 5, p<0.0001, partial Eta2=0.01) were 
significant but with small effect sizes. The interaction 
between mMRC and time was not significant (F1, 
20606=0.83, p=0.36, partial Eta2=0.00004), indicating that 
the rate of change in SGRQ over time did not vary by 
baseline mMRC status.
The ANOVA results in the medium-term dataset 
showed a similar difference: F1, 8939=437.6, p<0.0001, 
partial Eta2=0.05). Figure 4 shows that there was quite 
a large and consistent difference between the 2 groups 
of patients and patients with mMRC grades 1 and 2 
remained significantly better than at baseline at 24 
months (p=0.0017), but not at 36 months (p=0.06). In 
contrast, patients with mMRC grades 3 and 4 were 
numerically, but not significantly, worse than baseline 
from 12 months onwards. The linear effect for time was 
significant (F1, 8939=33.4, p<0.0001, partial Eta2=0.004), 
as was the quadratic effect (F1, 8939=29.6, p<0.0001, 
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partial Eta2=0.003), but the term for mMRC x time was 
not (F1, 8939=1.00, p=0.32, partial Eta2=0.0001, showing 
that there was no significant difference between groups 
in terms of change over time.
large 95% confidence intervals in mMRC grades 3 and 
4 patients, due to smaller numbers of trial participants 
contributing data at this time point, lend uncertainty 
to this observation. In medium-term trials, the patients 
with less dyspnea (mMRC grades 1 and 2) lose some 
benefit over time, but even after 36 months remain 
a little better when compared to baseline, whereas in 
mMRC grades 3 and 4 groups, benefit was lost at 12 
months and for the subsequent 2 years. It is not clear 
why there is a difference at 12 months between the 2 
groups of trials, but it may be due to inclusion criteria 
and participant demographics. The exacerbation rate 
and hospitalization rate in medium-term trials were 
both higher than in the short-term trials (Tables 1 and 
2) and there is an association between exacerbation rate 
and worsening of SGRQ score.8
It should be appreciated that this analysis did not 
compare bronchodilator treatment with placebo, but it 
looked at the SGRQ changes during the trial regardless 
of treatment arm, so some patients will have received 
active treatment, while others would have had placebo. 
As shown in a companion paper,9 in the context of 
a clinical trial, receiving placebo appears to be an 
active, albeit less effective, treatment that results in an 
improvement in SGRQ score that is progressive at onset 
and is sustained for many months. In that paper, we 
showed that while there was a clear difference in size of 
improvement in score between patients in low-medium 
versus high socio-economic countries, whether receiving 
active treatment or placebo, the difference between 
active treatment and placebo arms was minimally 
affected by socio-economic status. In this analysis, while 
there was a significant difference between patients who 
were more or less severe at baseline, the proportion of 
variance in SGRQ score explained by differences in 
baseline GOLD or mMRC grade was small and most of 
the partial Eta2 values would be judged to be small.6,7 
The same limitations apply to these analyses as they 
do to most other analyses from the CBQC database. 
While the database is made up of individual patient 
data from a large number of patients and trials, the 
comparisons are post hoc and largely indirect. The trials 
had different inclusion criteria and will, because of issues 
of sampling from a population, have included patients 
with different baseline characteristics. That having been 
said, the findings are quite consistent and show that, 
at a study population level, patients with more severe 
airflow limitation or more severe breathlessness, show a 
smaller SGRQ response to long-acting bronchodilators 
Discussion
This analysis shows that in both short- and medium-
term trials, patients in GOLD grades 1 and 2 showed 
a greater improvement in SGRQ score than those 
in GOLD grades 3 and 4. These differences were 
seen at nearly all time points. In short-term trials, the 
improvement in SGRQ score seen in GOLD grades 
1 and 2 was approximately double that observed in 
GOLD grades 3 and 4. Visually the responses appear 
to widen over time (Figure 1), although the effect size 
was negligible, despite the relatively large sample size. 
In the medium-term trials, benefit was maintained over 
3 years in GOLD grades 1 and 2 patients, but was lost 
by 24 months in GOLD grades 3 and 4 (Figure 2).
Using mMRC score as a measure of baseline severity, 
the findings were similar. In the short-term trials, the 
improvements were smaller in patients with worse 
dyspnea (i.e., mMRC grades 3 and 4). In short-term trials, 
there appears to be convergence at 12 months, but the 
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than less severe patients.
Taken overall, the conclusions from this analysis have 
implications for clinical trial design and analysis and 
suggest that pre-specified subgroup analysis by baseline 
severity should be undertaken. These analyses may also 
have implications for clinical practice, since they suggest 
that patients with less severe disease may respond 
better, and for longer, to a therapeutic intervention 
whether active treatment or just observation and 
monitoring. This should, perhaps, encourage doctors 
to treat milder patients more aggressively, since these 
analyses suggest that such patients may experience the 
greatest health status gain.
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